Well, if we needed further proof that Argenica were working in the right space, we have this statement posted by The Guardian ...
"The number of people in the UK experiencing a stroke will increase more than 50% to 151,000 a year by 2035, costing
the NHS and the economy £75bn in healthcare and lost productivity, stark new projections suggest."
Any reasonable improvement shown by ARG-007 in this current trial should grab the headlines across the world.
Interesting times girls and boys, interesting times.
As noted recently by the Perron Institute, about a possible rival (NA-1) ...
"Experiments by the team at Perron Institute have consistently found ARG-007 to be superior to NA-1, and critical new data
has demonstrated that the D-enantiomer of ARG-007 (i.e. peptide synthesised with D-arginine as opposed to L-arginine) to
be resistant to degradation by plasmin. This has important implications for ARG-007 to be potentially a much more useful
drug when used in combination with standard stroke care."
Possibly time for me to 'top up' again.
Opinion only of course.
- Forums
- ASX - By Stock
- AGN
- AGN Media thread
AGN Media thread, page-66
-
-
- There are more pages in this discussion • 220 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGN (ASX) to my watchlist
|
|||||
Last
80.0¢ |
Change
0.015(1.91%) |
Mkt cap ! $101.7M |
Open | High | Low | Value | Volume |
82.0¢ | 87.0¢ | 79.0¢ | $248.4K | 298.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2228 | 79.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
85.5¢ | 20500 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2228 | 0.790 |
3 | 22097 | 0.785 |
1 | 15000 | 0.775 |
3 | 25286 | 0.770 |
1 | 35000 | 0.765 |
Price($) | Vol. | No. |
---|---|---|
0.855 | 20500 | 2 |
0.860 | 10000 | 1 |
0.870 | 34639 | 3 |
0.875 | 1182 | 1 |
0.890 | 640 | 1 |
Last trade - 15.59pm 06/09/2024 (20 minute delay) ? |
Featured News
AGN (ASX) Chart |